Prolactin responses to buspirone challenges were examined in seven women with late luteal phase dysphoric disorder and the same number of healthy controls. The responses were found to be blunted during the follicular phase in the women with LLPDD suggesting that 5-HT1A receptor subsensitivity is perhaps a trait rather than a state marker for LLPDD.
TaylorD.L., MathewR.J., HoB.T.Serotonin levels and platelet uptake during premenstrual tension.Neuropsychobiology1984; 12: 16–18.
3.
AshbyC.R.Jr, CarrL.A., CookC.L.Alteration of platelet serotonergic mechanisms and monoamine oxidase activity in premenstrual syndrome.Biol Psychiatry1988; 24: 225–233.
4.
RojanskyN., HalbreichU., ZanderK.Imipramine receptor binding and serotonin uptake in platelets of women with premenstrual changes.Gynecol Obstet Invest1991; 31: 146–152.
5.
RapkinA.J., ReadingA.E., WooS.Tryptophan and neutral amino acids in premenstrual syndrome.Am J Obstet Gynecol1991; 165: 1830–1833.
6.
VeeningaA.T., WestenbergG.M.Serotonergic function in late luteal phase dysphoric disorder.Psychopharmacology1992; 108: 153–158.
7.
LeeM.A., NashJ.F., BarnesM.Inhibitory effect of ritanserin on the 5-hydroxytryptophan mediated cortisol and prolactin secretion in humans.Psychopharmacology1991; 103: 258–264.
8.
BancroftJ., CookA., DavidsonD.Blunting of neuroendocrine responses to infusion of L-tryptophan in women with perimenstrual mood change.Psychol Med1991; 21: 305–312.
9.
SmithC.E., WareS.J., CowenP.J.Pindolol decreases prolactin and growth hormone responses to intravenous L-tryptophan.Psychopharmacology1919; 103: 140–142.
10.
EndicottJ., HalbreichU.Retrospective reports of premenstrual depressive changes: factors affecting confirmation by daily ratings.Psychopharmacol Bull1982; 18: 109–112.
11.
HalbreichU., EndicottJ., SchactS.The diversity of premenstrual changes as reflected in the Premenstrual Assessment Form.Acta Psychiatr Scand1982; 65: 46–56.
12.
DinanT.G., BarryS., YathamL.N.The reproducibility of the prolactin response to buspirone: relationship to the menstrual cycle.Int Clin Pharmacol1990; 5: 119–123.
13.
YathamL.N., BarryS., DinanT.G.Serotonin receptors, buspirone, and premenstrual syndrome.Lancet1989; 1: 1447–1448.
14.
GregoryC.A., AndersonI.M., CowenP.J.Metergoline abolishes the prolactin response to buspirone.Psychopharmacology1990; 100: 383–384.
15.
NeuhauserH., LaakmanG., KnossallaA.Neuroendocrine effects of buspirone.Psychopharmacology1988; 96: 393.
16.
CoccaroE.F., GabrielS., SieverL.J.Buspirone challenge: preliminary evidence for a role for central 5HT1A receptor function in impulsive aggressive behaviour in humans.Psychopharmacol Bull1990; 26: 393–405.
17.
MeltzerH.Y., LeeH.S., NashJ.F.Jr.Effect of buspirone on prolactin secretion is not mediated by 5HT1A receptor stimulation.Arch Gen Psychiatry1992; 49: 163.
18.
NesseR.M., CurtisG.C., BrownG.M.Anxiety induced by flooding therapy for phobics does not elicit prolactin secretory response.Psychosom Med1980; 42: 25–31.
19.
LeschK.P.5HT1A receptor responsivity in anxiety disorders and depression.Prog Neuropsychopharmacol Biol Psychiatry1991; 15: 723–733.
20.
RubinowD.R., SchmidtP.J.Models for the development and expression of symptoms in premenstrual syndrome.Psychiatr Clin North Am1989; 12: 53–68.
